Alzheimer’s Disease: Pipeline Review, Developer Landscape and Competitive Insights 2019 –

May 2, 2019 Off By BusinessWire

Disease: Pipeline Review, Developer Landscape and Competitive Insights”

report has been added to’s

Alzheimer’s disease is a neurodegenerative condition characterized by
progressive memory loss, cognitive dysfunction and dementia. Currently,
it is the most commonly reported neurodegenerative disorder across the
world, and the sixth leading cause of death in the US. It was estimated
that, in 2018, nearly 5.7 million Americans (considering all age groups)
were living with Alzheimer’s disease. During the same year, Alzheimer’s
disease and other dementias were projected to be responsible for a
healthcare burden amounting to USD 277 billion, in the US. Considering
that only a limited range of diagnosis, treatment and disease management
solutions are presently available, this segment of the healthcare
industry is presently faced with a pressing need for accurate diagnostic
(predictive) tests and efficient treatment options that have the
capability to slow the progression of the condition.

Despite extensive research aimed at comprehending the etiopathogenesis
of Alzheimer’s disease, only six drugs have been approved since 1996 for
treatment. The rate of failure of drugs being developed for treating
Alzheimer’s disease is alarming (~99.6%) and is even higher than that
reported for cancer (~81%). Most of the existing therapeutic options
have proven inadequate in arresting the progression of the disease and
long-term management of associated symptoms. Currently, several
stakeholders in the pharmaceutical industry are engaged in efforts to
develop various types of disease-modifying interventions and
drug/therapy candidates that offer symptomatic relief. In fact, multiple
initiatives by start-ups are being backed by venture capital and other
strategic investors. In the coming years, the market is anticipated to
grow at a significant pace as more novel solutions clear clinical
evaluation and get commercialized.

Key Topics Covered:

  • Preface
  • Executive Summary
  • Introduction
  • Pipeline Review: Marketed and Clinical Drugs
  • Alzheimer’s Disease: Unmet Needs Analysis
  • Case Study: Terminated Drugs
  • Publication Analysis
  • Partnership and Collaborations
  • Funding and Investment Analysis
  • Non-Pharmacological Interventions and Diagnostics
  • Alzheimer’s Disease Therapy: Concluding Remarks
  • Executive Insights

Companies Mentioned

  • 23andMe
  • 3M
  • AB Science
  • Abbott
  • ACADIA Pharmaceuticals
  • Accera
  • Access Industries
  • Arrien Pharmaceuticals
  • Breakout Labs
  • Bristol-Myers Squibb
  • CarThera
  • CDC Enterprises
  • Cerebain Biotech
  • Cerecin
  • CereSpir
  • GCA Therapeutics
  • GemVax & Kael
  • GlaxoSmithKline
  • GliaCure
  • GliaPharm
  • GNT Pharma
  • Google
  • Optina Diagnostics
  • OrbiMed
  • P2D Bioscience
  • Pain Therapeutics
  • WuXi Biologics
  • Xcelthera
  • XoNovo
  • Ybrain
  • Zeltia

For more information about this report visit

About is the world’s leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.

Laura Wood, Senior Press Manager
[email protected]
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Alzheimer’s
Disease Drugs